Generic Name and Formulations:
Colchicine 0.6mg; caps.
Indications for MITIGARE:
Prophylaxis of gout flares.
Limitations Of use:
Not studied for acute treatment of gout flares during prophylaxis. Not for treating pain from other causes.
0.6mg once or twice daily; max 1.2mg/day.
Renal or hepatic impairment with concomitant CYP3A4 and P-gp dual inhibitors (life-threatening toxicity possible). Concurrent renal and hepatic impairment.
Monitor for toxicity; if present, consider temporary interruption or discontinuation. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid concomitant CYP3A4 inhibitors (eg, clarithromycin, ketoconazole, grapefruit juice, erythromycin, verapamil) and/or P-gp inhibitors (eg, clarithromycin, ketoconazole, cyclosporine); if unavoidable, reduce daily dose and monitor for colchicine toxicity. Concomitant statins, fibrates may potentiate myopathy and rhabdomyolysis.
Diarrhea, nausea, vomiting, abdominal pain; blood dyscrasias (myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia), neuromuscular toxicity, rhabdomyolysis, overdosage (may be fatal).
Clinical Pain Advisor Articles
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Greater Temporal Summation of Pain in HIV With Chronic Pain
- FDA Warns Two Companies About Bogus Opioid Addiction Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- A Potential Biomarker for Predicting Antibody Treatment Efficacy in Migraine